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Polycyclic Aromatic Hydrocarbon–DNA Adducts and Breast
Cancer: A Pooled Analysis
ABSTRACT. Polycyclic aromatic hydrocarbon (PAH)-DNA adducts have been associated
with breast cancer in several small studies. The authors’ pooled analysis included 873 cases
and 941 controls from a population-based case-control study. Competitive enzyme-linked
immunosorbent assay in peripheral mononuclear cells was conducted in 2 rounds, and
results were pooled on the basis of round-specific quantiles. The odds ratio for breast can-
cer was elevated in relation to detectable PAH-DNA adducts (1.29 as compared with non-
detectable adduct levels; 95% confidence interval  1.05, 1.58), but there was no apparent
dose-response relationship with increasing quantiles. No consistent pattern emerged when
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breast cancer risk. Details of the study method are
described elsewhere.12 The study was undertaken in
response to women’s concerns about the high incidence
rates of breast cancer in Nassau and Suffolk counties
(117.8 and 113.6 per 100,000 women, respectively,
from 1992–1996), and that breast cancer in this geo-
graphic area may be caused by exposure to environ-
mental contaminants.12 The primary aims of the LIBCSP
were to examine whether breast cancer incidence was
associated with PAH-DNA adducts or organochlorine
compounds in peripheral blood. This study was con-
ducted with approval from participating institutional
review boards and in accordance with an assurance
filed with and approved by the U.S. Department of
Health and Human Services.13
The study reported here is a pooled analysis based on
1,814 women who participated in the LIBCSP and who
donated a blood sample of sufficient volume to assess
PAH-DNA adduct levels using competitive enzyme-
linked immunosorbent assay (ELISA). Our previous
research8 was based on a sample of 999 of these Long
Island respondents (i.e., Round 1). The present report
provides results on the remaining 815 women who par-
ticipated in the LIBCSP and who donated sufficient
blood volume to conduct the assays (Round 2), as well
as the results of pooled analyses combining the data
from all 1,814 LIBCSP respondents (Rounds 1  2).
Study population. Eligible cases were defined as
women newly diagnosed with in situ or invasive breast
cancer between August 1, 1996, and July 31, 1997, who
were aged 20 yr or older, spoke English, and 
resided in Nassau or Suffolk county on Long Island,
New York, at the time of diagnosis. Eligible controls
were defined as women who were aged 20 yr or older,
spoke English, and resided in the same Long Island
counties as the cases but had no personal history of
breast cancer. (More than 97% of the population in
these 2 counties speaks English.12) Study staff identified
potentially eligible cases through frequent contact 
with pathology departments of regional Long Island and
New York City hospitals; the physician was approached
to confirm the patient’s study eligibility and to obtain
permission to contact her. Potentially eligible controls
were frequency-matched to the expected age distribu-
tion of the cases and identified through random-digit
dialing14 for women aged under 65 yr, and through
Health Care Finance Rosters for women aged 65 and
older.
the results were stratified by PAH sources (e.g., active cigarette smoking or PAH-containing
foods), or when the cases were categorized by stage of disease or hormone receptor status.
These data provide only modest support for an association between PAH-DNA adducts and
breast cancer development.
<Key words: air pollution, breast cancer, cigarette smoking, cooked meat, DNA adducts, pas-
sive smoking, polycyclic aromatic hydrocarbons>
POLYCYCLIC AROMATIC HYDROCARBONS (PAHs)
have been shown, in laboratory-based studies, to induce
mammary tumors,1 but their role in human breast car-
cinogenesis has not been established.2 PAH compounds
are ubiquitous; major exposure sources include active
and passive cigarette smoke, consumption of PAH-con-
taining foods (e.g., grilled and smoked foods and leafy
vegetables), and air pollutants (from industrial manufac-
turing, fires, and motor vehicle traffic).3,4 PAH com-
pounds are classified as probable or possible human
carcinogens.5 Cancer risk in humans (cancer of the lung,
for example) in relationship to PAH exposure varies with
an individual’s ability to detoxify or eliminate the con-
taminant. PAH-DNA adduct lesions are formed during
this multistep metabolic process, and their presence
suggests either high levels of exposure to the contami-
nant or the body’s inability to adequately respond to the
exposure, or both.6,7
Using PAH-DNA adducts as a body burden measure
of exposure and response, researchers in several epi-
demiologic studies observed a positive association with
breast cancer among women.8–11 Investigators who stud-
ied small, hospital-based series of patients reported at
least a doubling of breast cancer risk in relation to the
presence of DNA adducts.9–11 In contrast, a relatively
more modest 35% increase in breast cancer risk was
noted in relation to detectable PAH-DNA adducts in the
only investigation reported to date of a large (N  999)
population-based sample of cases and controls.8 No
increase in the odds ratios (ORs) for breast cancer was
observed with increasing adduct levels in the larger
study, nor was there any substantial variation associated
with several sources of PAH, such as active cigarette
smoking or consumption of grilled and smoked foods.8
These results are consistent with the hypothesis that
individual variation in response to the exposure may be
a more important influence on breast carcinogenesis
than the absolute exposure amount.8 To clarify such an
association, reports are needed from studies that include
large numbers of women drawn from the general 
population, and that employ state-of-the-art exposure
measurement and data collection methods.2
Materials and Method
The Long Island Breast Cancer Study Project (LIBCSP)
is a multi-institutional collaboration to determine
whether environmental factors are associated with
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Data collection. Potentially eligible subjects were
contacted by mail and telephone to confirm eligibility
and arrange for in-home personal interviews. Signed
informed consent was obtained from all women prior to
the interview. We conducted interviews with 1,508
cases (82%) and 1,556 controls (63%). Response rate
varied with age,12 with higher rates among cases and
controls under age 65 (88.9% and 76.1%, respectively)
than among those aged 65 and older (71.6% and
43.3%, respectively). The main questionnaire,14 which
was administered by a trained interviewer, sought infor-
mation on known and suspected risk factors for breast
cancer, including PAH exposure sources over the life
course (e.g., active cigarette smoking, exposure to pas-
sive smoking in the subject’s home, and intake of grilled
and smoked foods).15 The LIBCSP food frequency ques-
tionnaire,12 which gathered data on diet history during
the 12 mo prior to the interview, was self-completed by
98% of respondents and included questions on food
preparation methods. Nonfasting blood samples were
collected from nearly three-quarters of study partici-
pants (73% of cases and 73% of controls).
As previously published,12 an increase in breast can-
cer among women on Long Island was found to be asso-
ciated with lower parity, late age at first birth, little or no
breastfeeding, a family history of breast cancer, and
increasing income and education. Results were similar
when the analyses were restricted to respondents who
donated blood, or to those with DNA available for these
analyses (data not shown). Factors that were found to be
associated with a decreased likelihood that a respon-
dent, regardless of case-control status, would donate
blood12 included increasing age (1% decrease for each
year increase in age) and past active smoking (25%
decrease); factors associated with an increased proba-
bility included white or other race (65% and 74%
increase, respectively, vs. black race), alcohol use (28%
increase), ever breastfed (47% increase), ever used hor-
mone replacement therapy (63% increase), ever used an
oral contraceptive (21% increase), and ever had a mam-
mogram (51% increase). Case-control status and intake
of grilled and smoked foods were not predictors of
blood donation.8
Laboratory methods for Round 2. In Round 2, the
PAH-DNA adduct assays were conducted by the same
laboratory (Dr. Regina M. Santella, Columbia University,
New York, NY), using the same procedures that were
used to analyze the samples in Round 1.8 PAH diol-
epoxide-DNA adducts were analyzed by competitive
ELISA, using a previously described method.16,17
Samples were run with the lab blinded to case-control
status, in duplicate, and mean values were used for
determination of percentage inhibition. For analytical
purposes, those samples with  15% inhibition were
considered nondetectable and assigned a value of
1/108—an amount midway between the lowest positive
value and zero. The corresponding mean value and
standard deviation (SD) for the positive control run with
multiple batches was 7.8 (SD  3.10) (n  10) in Round 2.
As an additional quality control measure, 135 samples
were assayed in duplicate; there was no significant 
difference in mean adduct levels (mean difference 
–0.02; SD  3.24), paired t-test; p  0.93.
In Round 1, assays of PAH-DNA adducts were com-
pleted for a random sample of women with invasive
breast cancer (n  446) and for nearly all women with
in situ disease (n  129), as well as for a random sam-
ple of control women (n  424).8 For Round 2, PAH-
DNA adduct assays were completed for the remaining
subjects (276 with invasive breast cancer, 22 with in situ
breast cancer, and 517 controls) who had donated a
blood sample of adequate volume (about 25 ml) to yield
sufficient DNA for the PAH analyses (100 g or more of
DNA). To enhance the stability of our estimates for
women with in situ disease in our original report,8 we
included most of these women in Round 1. This sam-
pling strategy, however, altered the case:control ratio in
the 2 rounds. Nevertheless, risk factors among women
with PAH-DNA adduct results in either Rounds 1 or 2
and the pooled group (Rounds 1  2) did not differ 
systematically from all LIBCSP participants who donated
blood (data not shown).
Analysis of Round 2 samples was performed approxi-
mately 4.5 yr after Round 1. During the intervening
time, several assay materials changed, including the lot
of 96 microwell plates, the secondary antiserum, and
the benzo(a)pyrene diolepoxide adducts to lymphocyte
DNA (BPDE-DNA) standard. In Round 2, 50% inhibi-
tion in the competitive ELISA was approximately 3-fold
lower than in Round 1 and resulted in sample values
that were also lower than in Round 1. This difference
could have been caused by errors in quantitation of the
new standard, variations in dilution of primary or sec-
ondary antibodies, or plate differences. However, the
percentage of nondetectable samples was similar in
Round 1 (28.2%) and Round 2 (29.3%). This suggests
that the assay was working at a similar level of sensitiv-
ity both times, and that the problem was in the conver-
sion of percentage inhibition to absolute adduct level.
Statistical analysis for Round 2. We conducted all sta-
tistical analyses using SAS, version 8 (SAS Institute, Inc.,
Cary, NC). For statistical analysis of the data from Round 2,
we used the same methods as described for Round 1.8
Briefly, the raw lab data were log-transformed on a nat-
ural scale. We compared means and SDs of PAH-DNA
adduct levels (expressed as per 108 nucleotides) of cases
and controls using the unpaired Student’s t-test. The
ORs and corresponding 95% confidence intervals (CIs)
for breast cancer in relation to PAH-DNA adducts were
calculated using unconditional logistic regression,18
with adjustment for the frequency-matching factor of
age at reference (date of diagnosis for cases and date of
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identification for controls). We considered PAH-DNA
adduct levels as a continuous variable, dichotomized
into a single binary variable (detectable levels vs. non-
detectable levels), as well as categorized into quantiles.
We constructed PAH-DNA adduct quantiles based on
the distribution among the controls in Round 2, with
subjects with nondetectable levels of adducts catego-
rized in the lowest quantile of exposure; those with
detectable levels were grouped on the basis of their rank
order. Quantile ranges (per 108 nucleotides) for subjects
in Round 2 (n  815) were as follows: quantile 1, non-
detects; quantile 2,  0–3.8355; quantile 3, 
3.8355–5.9151; quantile 4,  5.9151–8.3407; quantile
5,  8.3407.
We assessed confounding by examining the percent-
age change in the OR. Covariates considered as poten-
tial confounders included age at menarche, parity,
number of live births, lactation, months of lactation, age
at first birth, number of miscarriages, history of fertility
problems, body mass index (BMI, weight [kg]/height
[m2]) at reference, BMI at age 20, weight, height, first
degree family history of breast cancer, history of benign
breast disease, menopausal status, oral contraceptive
use, hormone replacement use, race, ethnicity, educa-
tion, religion, marital status, season of blood donation,
total years of residence in the Long Island area, age first
moved to Long Island, length of residence in the inter-
view home, and income. Definitions of the covariates
used for these analyses have been published,8,12 except
for income. For the 11.5% of subjects with missing infor-
mation on household income in the year prior to the ref-
erent date, we assigned values derived from simple
regression models for case and control subjects that
included age, race, and education. Omission of subjects
with missing income information from the logistic mod-
els did not materially alter the estimates of effect for
PAH-DNA adducts. None of the covariates we evaluat-
ed changed the estimate by 7% or more when we con-
sidered them individually or in a backward-elimination
process that began with a full model (data not shown).
Thus, only the age-adjusted models are shown. We did
not include PAH sources, such as smoking or consump-
tion of grilled or smoked foods, in the models to evalu-
ate confounding.
Statistical analysis of pooled data. We pooled the data
from Rounds 1 and 2 to increase the stability and preci-
sion of the effect estimates for breast cancer associated
with PAH-DNA adduct levels, and to facilitate subgroup
analyses. We based the pooled analyses on 1,814 
subjects who participated in the LIBCSP and provided a
sufficiently large blood sample to conduct the adduct
assay (n  873 breast cancer cases and 941 controls).
For the pooled analyses, we combined the PAH-DNA
adduct data from Rounds 1 and 2 into 2 exposure vari-
ables: (1) a single binary variable (detectable/nonde-
tectable), and (2) round-specific quantiles (as described
above). We then performed unconditional multivariate
logistic regression using the same methods described
previously, except that a term indicating round (1 or 2)
was included. However, inclusion of this indicator
term for round did not materially change the esti-
mates, and thus only results without this indicator are
shown. None of the previously mentioned covariates
considered as potential confounders changed the 
estimate of effect by 5% or more (data not shown);
therefore, we did not include these covariates in the
results shown.
We used polytomous logistic regression19 to deter-
mine whether the ORs varied when the breast cancer
cases were partitioned on their tumor characteristics
(e.g., stage of disease [in situ vs. invasive] or a joint
measure of estrogen receptor [ER] and progesterone
receptor [PR] status), as reported in the subjects’ medical
records. We evaluated effect modification on a multi-
plicative scale by comparing the log-likelihood esti-
mates derived from unconditional logistic regression
models with and without an interaction term. Covariates
we considered as potential effect modifiers included
menopausal status, season of the blood draw, length of
residence in the interview home, age at diagnosis,
active cigarette smoking, a combined measure of active
cigarette smoking and exposure to passive smoking
(from the parent or spouse) in the home, alcohol intake,
and intake of grilled or smoked foods (as assessed in the
main questionnaire).8 An additional covariate we con-
sidered as a potential effect modifier was a measure of
total dietary benzo[a]pyrene (BaP), which is one of the
major components of PAH20 and an established car-
cinogen.5 The measure used in this analysis was a mod-
ification of a PAH food index developed recently by
Kazerouni et al.21 that uses data collected as part of the
diet history. Our estimates were modified to reflect the
assessment of cooking preparation methods for meat,
which were obtained as part of the LIBCSP food fre-
quency questionnaire. For each meat item reported, the
percentage of time a woman reported using a specific
cooking method was used to create weights. The BaP
values unique to that cooking method and doneness
level21 were then weighted. For each meat item, weighted
BaP levels for each cooking method were summed
across cooking methods. We multiplied the resulting
nanograms of BaP per gram for each meat item by the
woman’s intake (in grams) of that specific meat item. We
then categorized the estimated total BaP index levels
into quantiles based on the distribution in the control
group.
Results
Round 2 analyses. The mean level of PAH-DNA
adducts, expressed as per-108 nucleotides, among the
298 cases (5.48; SD  5.10) was only slightly higher
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than the corresponding adduct level in the 517 controls
(5.37; SD  6.90). The age-adjusted OR associated with
adduct levels, dichotomized into detectable vs. nonde-
tectable, was 1.23 (95% CI  0.90, 1.70). As shown in
Table 1, there was little evidence for a dose-response
relationship; the OR for breast cancer in relation to the
highest quantile of adduct levels, as compared with 
the lowest, was only modestly increased (age-adjusted
OR  1.24 for the highest quantile, as compared with
the lowest; 95% CI  0.80, 1.90). As found in Round 1,8
the ORs for detectable adducts were higher among 
premenopausal (OR  1.84; 95% CI  1.04, 3.27) than
among postmenopausal (OR  1.01; 95% CI  0.69,
1.50) women.
Pooled analyses. The mean levels of adducts for
LIBCSP participants, obtained from the Round 2 assays,
were appreciably lower for both cases and controls
than the values reported previously for the LIBCSP par-
ticipants in Round 1.8 However, the proportion of con-
trol subjects with nondetectable adducts was
comparable for Round 1 (28.2%) and Round 2 (29.3%),
indicating that the standard curves for Rounds 1 and 2
were relatively different, but that the sensitivity of the
method was nearly the same in both (see Materials and
Method). In addition, the elevation in the ORs of 1.23
associated with the detectable adducts, vs. nonde-
tectable adducts, observed in Round 2 is not substan-
tially different from the Round 1 estimate of 1.35.8
Further, there was no apparent dose-response relation-
ship with increasing levels of adducts in either Round 1
or Round 2.
As shown in Table 1, the age-adjusted OR for the
highest quantile of PAH-DNA adduct levels in the
pooled data was 1.41 (95% CI  1.07, 1.86). Again,
there was no consistent increase in the OR with increas-
ing quantiles of adduct levels. With the adduct levels
dichotomized, the age-adjusted OR for detectable vs.
nondetectable adducts was 1.29 (95% CI  1.05, 1.58).
The effect of adduct levels on breast cancer appeared
to be more pronounced among premenopausal women
(age-adjusted OR  1.56; 95% CI  1.09, 2.23) than
among postmenopausal women (corresponding OR 
1.14; 95% CI  0.88, 1.47) (Table 2), although the het-
erogeneity was not statistically significant on a multi-
plicative scale (p  0.05). Among postmenopausal
women, there was some variability in the estimates with
age (OR for 50–64 yr  1.20 [95% CI  0.83, 1.75]; 
for 65–74 yr  0.98 [95% CI  0.61, 1.56]; and for 75
yr  1.43 [95% CI  0.71, 2.88]), suggesting that the
increase in risk associated with detectable adducts is not
limited to premenopausal women only. ORs varied little
when cases were categorized by stage of disease or hor-
mone receptor status.
As shown in Table 3, there was some variation in the
ORs associated with PAH-DNA adduct levels when sub-
jects were subgrouped on the basis of their self-reported
exposure to PAH sources. For example, when we used a
conventional smoking exposure measure that considers
only active smoking status, the OR for adducts was
increased by 48% among nonsmokers, but there was no
increase among current smokers. In contrast, use of an
exposure measure that takes into consideration active
cigarette smoking as well as exposure to passive ciga-
rette smoke in the residential home resulted in an OR for
adducts that was decreased by 35% among those who
reported no active or residential passive smoking expo-
sure, but was increased by 82% among those reporting
only passive smoke exposure in the home, by 67%
Table 1.—Age-Adjusted ORs for Breast Cancer and 95% CIs in Relation to PAH-DNA Adduct Levels for Subjects with Blood Analyzed
in Round 2 and for All Subjects with Analyzed Blood
Subjects with blood analyzed in Round 2 All subjects with analyzed blood*
(n = 815) (N = 1,814)




DNA adduct level† n n OR 95% CI n n OR 95% CI
1‡ 80 159 1.00 228 293 1.00
2 51 90 1.18 0.76, 1.83 156 163 1.26 0.95, 1.67
3 66 89 1.51 0.99, 2.29 175 161 1.40 1.06, 1.85
4 46 90 1.02 0.65, 1.60 137 163 1.09 0.82, 1.45
5 55 89 1.24 0.80, 1.90 177 161 1.41 1.07, 1.86
Notes: OR  odds ratio, CI  confidence interval, and PAH  polycyclic aromatic hydrocarbon. Data from the Long Island Breast Cancer
Study Project, 1996–1997.13
*Pooled analysis (n  1,814) included all subjects with blood analyzed in Round 2 (n  815), plus subjects with blood analyzed in Round 1
(n  999; see Gammon et al.).8
†Quantile ranges for subjects with blood analyzed in Round 2 (n  815): Quantile 1, nondetects; Quantile 2,  0–3.8355; Quantile 3,
 3.8355–5.9151; Quantile 4,  5.9151–8.3407; Quantile 5,  8.3407. Quantiles were pooled for subjects with blood analyzed in Rounds
1 and 2; therefore, quantile ranges are specific to each round.
‡Includes all subjects with nondetectable DNA adduct levels.
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among those reporting only active smoking, and by 6%
among those reporting both exposures.
The relationship between adducts and breast cancer
also varied with the season in which the blood was
drawn (Table 3), with a more than 2-fold increase in the
OR for adducts among those who donated blood during
the winter (defined as December 21–March 20), in 
contrast to a 17% decrease in the OR among those 
who donated blood in the summer months (June
21–September 20). There was some heterogeneity in the
relationship between adducts and breast cancer when
the results were stratified by dietary sources of PAH,
including grilled or smoked foods, in the most recent
decade as assessed in the main questionnaire, or the
index of total dietary BaP derived from the food fre-
quency questionnaire. For example, the OR for adducts
was reduced by 15% among those in the lowest quan-
tile of BaP intake from food, but was elevated by 69%
among those with the highest intake of BaP from food.
However, none of the variations observed across sub-
groups was statistically significant. Further, there was no
variation in the OR with alcohol intake.
Discussion
We based our analyses on data collected in 1996 
and 1997 as part of the LIBCSP; however, the assays to
determine PAH-DNA adduct levels were conducted in
2 separate rounds because of budgetary constraints.
We reported the results from Round 1 previously,8 and
we report the results from Round 2 here. Analyses
from Rounds 1 and 2 yielded similar results for the
main effects of PAH-DNA adducts on breast cancer
incidence: the magnitude of the association was less
than 2.0, the magnitude was not appreciably con-
founded by known or suspected risk factors for breast
cancer, and there was no apparent dose-response
relationship.
We then pooled data from Rounds 1 and 2, and the
results from these analyses were based on data for
1,814 women; however, the observed CIs from the
pooled analyses were not directly comparable with
those in either round alone. The pooled analyses
revealed a 29% increase in the incidence of breast can-
cer in relation to detectable, as compared with nonde-
tectable, PAH-DNA adducts. In subgroup analyses, the
OR for adducts was more pronounced among pre-
menopausal than postmenopausal women, but the
interaction with menopausal status was not statistically
significant. Also, the OR was higher among women
who donated their blood sample in winter as compared
with the other seasons, but again, the variation in the
effect estimates was not significant. There was no vari-
ation in the ORs associated with PAH-DNA adduct 
Table 2.—Age-Adjusted ORs for Breast Cancer and 95% CIs in Relation to Detectable 
PAH-DNA Adduct Levels for All Subjects with Analyzed Blood
Cases Controls
Age-adjusted
Stratifying factor n n OR 95% CI
Main effect 873 941 1.29 1.05, 1.58
Menopausal status
Premenopausal 279 319 1.56 1.09, 2.23
Postmenopausal 572 585 1.14 0.88, 1.47
Unknown 22 37
Length of residence in interview home
<15 yr 345 375 1.44 1.05, 1.99
15 yr 511 544 1.27 0.97, 1.67
Unknown 17 22
Age at diagnosis
<65 yr 586 713 1.39 1.09, 1.77
65 yr 287 228 1.08 0.73, 1.58
Stage*
In situ 151 941 1.21 0.83, 1.78
Invasive 722 941 1.30 1.05, 1.62
ER and PR status*
ER/PR 355 941 1.39 1.05, 1.83
ER/PR 79 941 1.29 0.76, 2.18
ER/PR 28 941 1.35 0.57, 3.21
ER/PR 106 941 1.33 0.84, 2.10
Notes: OR  odds ratio; CI  confidence interval; PAH  polycyclic aromatic hydrocarbon; 
ER  estrogen receptor; PR  progesterone receptor. Pooled analysis (N  1,814) included all
subjects with blood analyzed in Round 2 (n = 815) plus subjects with blood analyzed in Round
1 (n  999; see Gammon et al.).8 Data from the Long Island Breast Cancer Study Project,
1996–1997.13
*Modeled using polytomous regression analysis.
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levels with the breast cancer cases’ stage of disease or
hormone receptor status.
These pooled results are based on the largest study
published to date on the issue of PAH-DNA adducts and
breast cancer incidence that also included comprehen-
sive assessment of many known and suspected risk fac-
tors for breast cancer. The large sample size permitted
further evaluation of results noted in previous reports. In
contrast to our earlier report based on data from Round
18—for which a higher OR for women with ERPR
tumors was noted—in our larger pooled analysis, we
observed no variation in the OR for adducts when case
women were stratified by the hormone receptor status of
their tumor. Yasui and Potter22 demonstrated that the
age-incidence curve of hormone-receptor–positive
tumors reflects the curve associated with the increasingly
higher rates observed in Western societies, whereas the
age-incidence curves for the other tumor types (hormone-
negative or hormone-discordant) reflect those associat-
ed with the lower rates observed in Asia. Because of the
potential public health importance of identifying factors
that contribute to the development of ERPR tumors,
further research is needed on whether adducts are asso-
ciated with hormone receptor status.
Concerns with the LIBCSP data collection methods
include a lower response rate among controls than
among cases, which was due primarily to the low par-
ticipation among women aged 65 yr and older.12 If the
older respondents in the LIBCSP somehow differed sys-
tematically from nonrespondents, our results may not be
Table 3.—Age-Adjusted ORs for Breast Cancer and 95% CIs in Relation to Detectable 
PAH-DNA Adduct Levels for All Subjects with Analyzed Blood
Cases Controls
Age-adjusted
Stratifying factor n n OR 95% CI
Main effect 873 941 1.29 1.05, 1.58
Active cigarette smoking exposure
Never 388 429 1.48 1.10, 2.00
Former 309 336 1.23 0.86, 1.76
Current 176 174 0.99 0.62, 1.58
Unknown 0 2
Active or passive cigarette smoking
Never either 75 90 0.65 0.34, 1.24
Ever passive only 304 331 1.82 1.28, 2.57
Ever active only 68 80 1.67 0.79, 3.52
Ever both 406 417 1.06 0.77, 1.44
Unknown 20 23
Alcohol intake
Never 308 333 1.21 0.86, 1.70
Ever 565 608 1.34 1.04, 1.74
Intake of grilled or smoked foods in most recent decade of life*
Quantile 1 186 209 0.79 0.51, 1.24
Quantile 2 165 182 1.45 0.90, 2.36
Quantile 3 174 173 1.51 0.95, 2.42
Quantile 4 146 174 1.21 0.73, 2.01
Quantile 5 167 166 1.52 0.94, 2.45
Unknown 35 37
Total dietary BaP index (ng/g)*
Quantile 1 173 180 0.85 0.53, 1.36
Quantile 2 178 172 1.33 0.83, 2.14
Quantile 3 182 180 1.37 0.87, 2.16
Quantile 4 163 183 1.80 1.10, 2.94
Quantile 5 147 191 1.69 1.05, 2.73
Unknown 30 35
Season
Winter 167 215 2.19 1.37, 3.48
Spring 223 279 1.33 0.91, 1.94
Summer 189 192 0.83 0.51, 1.37
Fall 294 255 1.06 0.73, 1.55
Notes: OR  odds ratio; CI  confidence interval; PAH  polycyclic aromatic hydrocarbon;
BaP  benzo[a]pyrene. Pooled analysis (N  1,814) included all subjects with blood analyzed
in Round 2 (n  815) plus subjects with blood analyzed in Round 1 (n  999; see Gammon 
et al.).8 Data from the Long Island Breast Cancer Study Project, 1996–1997.13
*Dietary quantiles were categorized using the distribution in the control group for the total
population of subjects that responded to the main questionnaire, regardless of whether their
blood was analyzed.
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generalizable to older women. Also, blood donors dif-
fered from nondonors,12 although there were no sub-
stantial differences in factors found to be associated
with breast cancer in the 3 sets of data (i.e., all inter-
viewed subjects, those with blood samples, and those
with DNA assay). Nevertheless, there is the possibility
that selection bias might have affected our study results.
None of the known or suspected risk factors assessed as
part of the LIBCSP substantially confounded or modified
our pooled analyses, including those factors that were
found to influence a subject’s probability of donating a
sample. Furthermore, the proportion of eligible subjects
who were willing to donate blood was comparable with
other population-based studies with a phlebotomy com-
ponent.23 Thus, it was unlikely that the factors that influ-
ence a subject’s willingness to provide blood unduly
affected our results.
A strength of the LIBCSP was the inclusion of a bio-
marker of exposure, rather than reliance on subject
recall of past exposures. As reviewed by Santella et al.,17
adducts reflect both PAH exposure and the body’s
response. PAHs are detoxified in the body through P450
and glutathione s-transferase (GST) pathways, and
incomplete detoxification results in DNA damage,
which can be reversed by normal DNA repair mecha-
nisms. Susceptible persons for whom such exposure is
very high, or those with genetic variations in the P450
and GST pathways or DNA repair mechanisms, yield
detectable DNA adduct levels. With the use of such a
biomarker, knowledge of the exposure source or the
exact genetic susceptibility mechanism need not be
characterized precisely. A drawback of this biomarker,
however, is that it does not reflect long-term exposure.
Instead, because PAH exposure is ubiquitous, it can per-
haps be interpreted as an internal dose from recent
exposures that reflects how the body would have been
likely to respond to such exposures in the past.
Our results were based on a measure of PAH-DNA
adducts assessed in peripheral mononuclear cells; other
investigators have asserted that this approach may yield
lower effect estimates than when adducts are measured
in breast tissue.24 The lower ORs reported here, and in
our earlier report,8 might have been caused by attenua-
tion, which is frequently observed when studies with
larger sample sizes yield more stable estimates of
effect.25,26 The stronger effects reported by others10 were
based on small numbers of subjects and were therefore
more likely to result in less-stable effect estimates.
Research based on large numbers of subjects and multi-
ple exposure assessment methods would help to clarify
this issue.
In our pooled analyses based on 1,814 subjects, pre-
menopausal women had a higher OR for PAH-DNA
adducts than postmenopausal women. In our previous
Round 1 analysis8 of 999 women, the variation in the
OR with menopausal status was less pronounced than
that of Round 2. However, in age-specific analyses
among postmenopausal women, most age groups had
elevated ORs for detectable adducts. Premenopausal
women were not hypothesized a priori to be a high-risk
subgroup. Other studies that have explored the associa-
tion between adducts and breast cancer have had too
few women to adequately conduct subgroup analyses.
Additional research is needed to clarify this issue and, if
the association is confirmed, to identify potential under-
lying mechanism(s) for the heterogeneity in risk by
menopausal status.
Also in our pooled analyses, we observed inconsistent
variation in ORs when the association between PAH-
DNA adducts and breast cancer was stratified by various
measures of PAH exposure. When we considered only
active smoking, we noted the lowest OR among women
who reported current active smoking, which has been
associated with high levels of PAH exposure.16
However, when we considered active smoking and
exposure to passive smoke in the home together, the
lowest OR was among those who reported neither expo-
sure. Also, we noted a higher OR among women with
blood collected during the winter months—a season
that others have associated with high BaP air concentra-
tion measurements.27 The OR for breast cancer and
adducts also varied somewhat with intake of PAH-
containing foods, regardless of the measure used, with a
reduced OR for those in the lowest quantile of intake
and an elevated OR for all other levels of intake. The
inconsistent pattern of the ORs across varying levels of
PAH exposure confirms that the detection of PAH-DNA
adducts may not be associated with higher levels of
exposure,28 but may instead identify subjects particular-
ly susceptible to the effects of PAH.
In a recent laboratory study,29 researchers found that
when human mammary epithelial cells were exposed to
physiologically relevant concentrations of ethanol prior
to dosing with BaP, adduct formation was enhanced.
However, in our pooled sample of 1,814 women, the
association between breast cancer and PAH-DNA
adducts was not modified by alcohol intake.
Further research with sufficiently large sample sizes is
needed to confirm our observation that PAH-DNA
adducts are associated with a modest increase in breast
cancer incidence, and to explore whether the effect dif-
fers with variations in genetic polymorphisms or other
markers of susceptibility. In addition, although active
cigarette smoking does not appear to be associated with
breast cancer,30 whether breast cancer is associated with
other key sources of PAH exposures (e.g., ambient
sources such as air pollution, environmental tobacco
smoke, and food; or occupational sources31) would also
be of interest. To advance research in this area, well-
conducted studies with multiple exposure-assessment
methods and based on large numbers of women are
needed.2
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